Mereo BioPharma Group plc American Depositary Shares Share Price
NASDAQ: MREO | Micro CapMereo BioPharma Group plc American Depositary Shares Stock Performance
Open $0.30 | Prev. Close $0.31 | Circuit Range N/A |
Day Range $0.29 - $0.30 | Year Range $0.20 - $2.36 | Volume 2,967 |
Average Traded $0.30 |
Mereo BioPharma Group plc American Depositary Shares Share Price Today
As of 10 August 2026, Mereo BioPharma Group plc American Depositary Shares's share price is $0.30. The stock opened at $0.30, compared to its previous close of $0.31. During today's trading session, Mereo BioPharma Group plc American Depositary Shares's share price traded between $0.29 and $0.30, with an average price of $0.30. Over the past 52 weeks, the stock has recorded a high of $2.36 and a low of $0.20. In terms of performance, Mereo BioPharma Group plc American Depositary Shares's share price has declined by 18.74% over the last six months and is down 82.60% on a year-on-year basis.
Mereo BioPharma Group plc American Depositary Shares Share Price Chart
Mereo BioPharma Group plc American Depositary Shares Stock Fundamentals & Key Indicators
Market Cap $236.43M | PE Ratio (TTM) -5.93 | Dividend Yield N/A |
EPS (TTM) $-0.05 | Revenue (TTM) $500000.00 | Return On Equity (TTM) -102.35% |
Profit Margin -8375.60% | Debt to Equity 0.12 | Quarterly Earnings Growth YoY 42.68% |
Mereo BioPharma Group plc American Depositary Shares Quarterly Profit & Loss
All figures in USD
Mereo BioPharma Group plc American Depositary Shares Annual Profit & Loss
All figures in USD
About Mereo BioPharma Group plc American Depositary Shares
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Mereo BioPharma Group plc American Depositary Shares Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.34 | $0.30 | -14.45% |
Jul 2026 | $0.32 | $0.35 | +5.81% |
Jun 2026 | $0.33 | $0.33 | -4.66% |
May 2026 | $0.27 | $0.34 | +27.51% |
Apr 2026 | $0.35 | $0.27 | -19.94% |
Mar 2026 | $0.36 | $0.34 | -7.95% |
Feb 2026 | $0.45 | $0.36 | -17.98% |
Jan 2026 | $0.44 | $0.45 | +6.97% |
Dec 2025 | $1.81 | $0.42 | -77.63% |
Nov 2025 | $1.91 | $1.86 | -1.85% |
Oct 2025 | $2.05 | $1.90 | -8.01% |
Sep 2025 | $1.74 | $2.06 | +20.82% |
MREO Share Price FAQs
What is Mereo BioPharma Group plc American Depositary Shares share price today?
What is the 52 week high and 52 week low of Mereo BioPharma Group plc American Depositary Shares stock?
What is MREO's market capitalisation today?
What is MREO's net income for the last quarter?
What is the 5 year returns of MREO?
What is the high & low stock price of MREO today?
Can I buy MREO shares in India?